2012 Annual Report  Key Products  Net sales of key products represented 84% of total net sales in 2012, 86% in 2011 and 84% in 2010. The following table presents U.S. and  international net sales by key product, the percentage change from the prior period and the foreign exchange impact when compared to the prior  period. Commentary detailing the reasons for significant variances for key products is provided below:  9  ** Change in excess of 100%.  % Change  Attributable to  Year Ended December 31,  % Change  Foreign Exchange  Dollars in Millions 2012 2011 2010 2012 vs.  2011  2011 vs.  2010  2012 vs. 2011  2011 vs. 2010  Key Products  Plavix  (clopidogrel bisulfate)  $  2,547  $  7,087 $  6,666   (64)% 6 %  -   -  U.S.   2,424   6,709  6,236  8 Non-U.S.   123   378  430   (67)%  (12)%  (1)% 3 % Avapro / Avalide (irbesartan/irbesartan-hydrochlorothiazide)   503   952  1,176   (47)%  (19)%  (1)% 2 % U.S.   155   549  679   (72)%  -   -  Non-U.S.   348   403  497   (14)%  (19)%  (3)% 4 % Eliquis  (apixaban)   2  N/A N/A N/A  N/A N/A N/A  U.S.   -   -   -  Non-U.S.   2  N/A N/A N/A  N/A N/A  N/A  Abilify  (aripiprazole)   2,827   2,758  2,565  3 % 8 %  (1)% 2 % U.S.   2,102   2,052  1,971  2 4  -   -  Non-U.S.   725   706  594  3 % 19 %  (7)% 6 % Reyataz  (atazanavir sulfate)   1,521   1,569  1,479   (3)% 6 %  (3)% 2 % U.S.   783   771  766  2 % 1  -   -  Non-U.S.   738   798  713   (8)% 12 %  (6)% 5 % Sustiva  (efavirenz) Franchise   1,527   1,485  1,368  3 % 9 %  (2)% 2 % U.S.   1,016   950  891  7 7  -   -  Non-U.S.   511   535  477   (4)% 12 %  (5)% 5 % Baraclude  (entecavir)   1,388   1,196  931  16 % 28 %  (2)% 5 % U.S.   241   208  179  16  -   -  Non-U.S.   1,147   988  752  16 % 31 %  (2)% 6 % Erbitux  (cetuximab)   702   691  662  2 % 4 %  -   -  U.S.   688   681  654  1 Non-U.S.   14   10  8  40 % 25 %  (2)% 5 % Sprycel  (dasatinib)   1,019   803  576  27 % 39 %  (4)% 3 % U.S.   404   299  190  35 57  -   -  Non-U.S.   615   504  386  22 % 31 %  (6)% 6 % Yervoy  (ipilimumab)   706   360  N/A 96 % N/A  N/A  N/A  U.S.   503   323  56  -   -  Non-U.S.   203   37  N/A **  N/A  N/A  N/A  Orencia  (abatacept)   1,176   917  733  28 % 25 %  (2)% 2 % U.S.   797   621  552  13  -   -  Non-U.S.   379   296  181  28 % 64 %  (6)% 8 % Nulojix  (belatacept)   11   3 N/A **  N/A N/A  N/A  U.S.   9   -   -  Non-U.S.   2   - N/A N/A  N/A N/A  N/A  Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)   709   473  158  50 % **  (2)% 3 % U.S.   516   346  121  49  -   -  Non-U.S.   193   127  37  52 % **  (9)% ** 